- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 492920, 8 pages
doi:10.1155/2012/492920
Modulation of Immunity by Antiangiogenic Molecules in Cancer
1INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, France
2Service d’Immunologie Biologique, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
3Service d’Hépatogastro-Entérologie et d’Oncologie Digestive, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
Received 27 July 2012; Accepted 10 December 2012
Academic Editor: W. Kast
Copyright © 2012 Magali Terme et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
In the last decades a new class of therapeutic drugs have been developed that block tumor angiogenesis. These antiangiogenic molecules, which target VEGF or VEGFR, PDGFR, and c-kit, can act not only on endothelial cells but also on immune cells. Some antiangiogenic molecules inhibit the development of immunosuppressive mechanisms developed by the tumors to escape the immune system (such as regulatory T cells, myeloid-derived suppressor cells, and immunosuppressive cytokines). These immunomodulatory effects must be characterized in detail to enable a better prescription of these treatments. In this paper we will focus on the impact of anti-angiogenic drugs on immunosuppression and their potential combination with immunotherapeutic strategies. Interestingly, immune parameters or their modulation during treatment could serve as potential biomarkers of response or resistance to anti-angiogenic therapies.